CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter study

Basit Öğe Kaydı
dc.authoridAyer, Mesut/0000-0003-1977-0104
dc.authoridKaynar, Leylagul/0000-0002-2035-9462
dc.authoridOz Puyan, Fulya/0000-0001-5853-0109
dc.authoridKirkizlar, Onur/0000-0001-7523-8599
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridYILDIRIM, MURAT/0000-0001-6416-9575
dc.authoridCan, Ferda/0000-0002-9899-1441
dc.authorwosidAyer, Mesut/U-5707-2018
dc.authorwosidKaynar, Leylagul/F-6991-2013
dc.authorwosidOz Puyan, Fulya/A-7077-2018
dc.authorwosidPınar, İbrahim/JWP-2738-2024
dc.authorwosidKirkizlar, Onur/W-9594-2018
dc.authorwosidPaydas, Semra/F-3132-2018
dc.authorwosidKeklik, Fatma/IZQ-0529-2023
dc.contributor.authorDemirci, Ufuk
dc.contributor.authorKirkizlar, Hakki Onur
dc.contributor.authorUmit, Elif G.
dc.contributor.authorGursoy, Vildan
dc.contributor.authorPinar, Ibrahim Ethem
dc.contributor.authorOzkalemkas, Fahir
dc.contributor.authorGuven, Zeynep Tugba
dc.date.accessioned2024-06-12T10:59:37Z
dc.date.available2024-06-12T10:59:37Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractDiffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality in a specific manner, morphology, and immunohistochemistry remain the backbone. We aimed to evaluate the value of CD5 expression on disease characteristics as well as prognosis in patients with DLBCL. Data of 131 patients with DLBCL with CD5 positivity and as a comparison arm, data of 129 patients with DLBCL without CD5 positivity were evaluated. Mean age was 59 and 55.7% of the patients were male. Overall survival was 29.8 months. Poor prognostic factors including (high-LDH levels, B symptoms, low ECOG score, high R-IPI and NCCN-IPI score) were observed to be significantly related with CD5 positivity. Mean survival in CD5 positive patients were 29.8 months, which is significantly shorter than the general DLBCL survival worldwide. CD5 expression shall be evaluated in all samples of DLBCL patients due to its possible effects on outcomes.en_US
dc.identifier.doi10.1007/s12308-022-00523-6
dc.identifier.endpage213en_US
dc.identifier.issn1868-9256
dc.identifier.issn1865-5785
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85143634789en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage203en_US
dc.identifier.urihttps://doi.org/10.1007/s12308-022-00523-6
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20497
dc.identifier.volume15en_US
dc.identifier.wosWOS:000905040100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofJournal Of Hematopathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiffuse Large B-Cell Lymphomaen_US
dc.subjectCD 5en_US
dc.subjectDoubleen_US
dc.subjectTriple Expressoren_US
dc.subjectCNS Prophylaxisen_US
dc.subjectC-MYCen_US
dc.subjectExpressionen_US
dc.subjectClassificationen_US
dc.subjectRituximaben_US
dc.subjectDiagnosisen_US
dc.titleCD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu